Dabrafenib for treatment of BRAF-mutant melanoma

by Kainthla, Radhika, Kim, Kevin B, Falchook, Gerald S
Published 2013

Arginine deprivation therapy for malignant melanoma

by Yoon, Jung-Ki, Frankel, Arthur E, Feun, Lynn G, Ekmekcioglu, Suhendan, Kim, Kevin B
Published 2012

Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report

by Kim, Dae Won, Barcena, Edelyn, Mehta, Urvi N, Rohlfs, Michelle L, Kumar, Ashok J, Penas-Prado, Marta, Kim, Kevin B
Published 2015

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance

by Wheler, Jennifer, Yelensky, Roman, Falchook, Gerald, Kim, Kevin B, Hwu, Patrick, Tsimberidou, Apostolia M, Stephens, Philip J, Hong, David, Cronin, Maureen T, Kurzrock, Razelle
Published 2015

Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma

by Hong, David S., Kurzrock, Razelle, Falchook, Gerald S., Andresen, Corina, Kwak, Jennifer, Ren, Min, Xu, Lucy, George, Goldy C., Kim, Kevin B., Nguyen, Ly M., O'Brien, James P., Nemunaitis, John
Published 2015

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-depende...

by Kefford, Richard, Sullivan, Ryan J, Miller, Wilson H, Elez, Elena M, Tan, Daniel, Kim, Kevin B, Long, Georgina V, Flaherty, Keith T, Tai, David, Stutvoet, Simone, Maacke, Heiko, Whiley, Matt, Parseval, Laure Moutouh-de, Tabernero, Josep
Published 2014

BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling

by Vin, Harina, Ojeda, Sandra S, Ching, Grace, Leung, Marco L, Chitsazzadeh, Vida, Dwyer, David W, Adelmann, Charles H, Restrepo, Monica, Richards, Kristen N, Stewart, Larissa R, Du, Lili, Ferguson, Scarlett B, Chakravarti, Deepavali, Ehrenreiter, Karin, Baccarini, Manuela, Ruggieri, Rosamaria, Curry, Jonathan L, Kim, Kevin B, Ciurea, Ana M, Duvic, Madeleine, Prieto, Victor G, Ullrich, Stephen E, Dalby, Kevin N, Flores, Elsa R, Tsai, Kenneth Y
Published 2013

Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

by Janku, Filip, Angenendt, Philipp, Tsimberidou, Apostolia M., Fu, Siqing, Naing, Aung, Falchook, Gerald S., Hong, David S., Holley, Veronica R., Cabrilo, Goran, Wheler, Jennifer J., Piha-Paul, Sarina A., Zinner, Ralph G., Bedikian, Agop Y., Overman, Michael J., Kee, Bryan K., Kim, Kevin B., Kopetz, E. Scott, Luthra, Rajyalakshmi, Diehl, Frank, Meric-Bernstam, Funda, Kurzrock, Razelle
Published 2015

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

by Janku, Filip, Angenendt, Philipp, Tsimberidou, Apostolia M., Fu, Siqing, Naing, Aung, Falchook, Gerald S., Hong, David S., Holley, Veronica R., Cabrilo, Goran, Wheler, Jennifer J., Piha-Paul, Sarina A., Zinner, Ralph G., Bedikian, Agop Y., Overman, Michael J., Kee, Bryan K., Kim, Kevin B., Kopetz, E. Scott, Luthra, Rajyalakshmi, Diehl, Frank, Meric-Bernstam, Funda, Kurzrock, Razelle
Published 2015

Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma

by Siroy, Alan E., Boland, Genevieve M., Milton, Denái R., Roszik, Jason, Frankian, Silva, Malke, Jared, Haydu, Lauren, Prieto, Victor G., Tetzlaff, Michael, Ivan, Doina, Wang, Wei-Lien, Torres-Cabala, Carlos, Curry, Jonathan, Roy-Chowdhuri, Sinchita, Broaddus, Russell, Rashid, Asif, Stewart, John, Gershenwald, Jeffrey E., Amaria, Rodabe N., Patel, Sapna P., Papadopoulos, Nicholas E., Bedikian, Agop, Hwu, Wen-Jen, Hwu, Patrick, Diab, Adi, Woodman, Scott E., Aldape, Kenneth D., Luthra, Rajyalakshmi, Patel, Keyur P., Shaw, Kenna R., Mills, Gordon B., Mendelsohn, John, Meric-Bernstam, Funda, Kim, Kevin B., Routbort, Mark J., Lazar, Alexander J., Davies, Michael A.
Published 2014